{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-21-143985","form_type":"8-K","ticker":"NNVC","cik":"0001379006","company_name":"NANOVIRICIDES, INC.","filed_at":"2021-11-26T23:59:59+00:00","discovered_at":"2026-05-14T18:04:12.294533+00:00","generated_at":"2026-06-28T05:17:16.271102+00:00","sec_items":["5.07"],"event_type":"other","sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.15,"confidence":"high","headline":"NanoViricides shareholders re-elect Anil Diwan, approve preferred stock grant and advisory vote frequency","bullets":["Anil Diwan re-elected as Class I director with 5,242,989 votes for, 137,944 withheld.","Shareholders approved a three-year interval for advisory vote on executive compensation (4,925,150 votes for).","Approved grant of 10,204 Series A Preferred Shares to Anil Diwan (5,028,342 for, 343,312 against, 34,352 abstain).","Ratified EisnerAmper as independent auditor for fiscal year ending June 30, 2022 (8,638,812 for, 372,551 against).","60.7% quorum achieved at the November 20, 2021 annual meeting."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-21-143985","json":"https://secwatch.observer/filing/0001104659-21-143985.json","markdown":"https://secwatch.observer/filing/0001104659-21-143985.md","text":"https://secwatch.observer/filing/0001104659-21-143985.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1379006/000110465921143985/0001104659-21-143985-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1379006/000110465921143985/tm2134013d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-28T05:17:16.271102+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}